Klivira
Request demo

Aetna Tysabri Prior Authorization: Navigating Requirements

Successfully navigating **Aetna Tysabri prior authorization** requires a precise understanding of submission channels, medical necessity criteria, and appeal pathways to minimize delays and denials.

For revenue cycle directors and prior authorization teams, managing high-volume specialty drug PAs like Tysabri (natalizumab), indicated for conditions such as multiple sclerosis and Crohn's disease, presents significant operational challenges. Klivira integrates directly with EMRs and payer systems to automate the complex requirements of Aetna's medical and pharmacy benefit review processes, enhancing efficiency and compliance.

Understanding Aetna's Prior Authorization Channels for Tysabri

Tysabri (natalizumab) is a high-cost specialty medication, often a target for prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. Its prior authorization pathway with Aetna depends on whether it falls under the medical or pharmacy benefit. Aetna utilizes distinct submission channels, including the Availity provider portal, X12 278 transactions, and ePA partners.

Medical Benefit Prior Authorization for Tysabri

For Tysabri administered under the medical benefit (e.g., infused in an outpatient setting), Aetna primarily routes precertification requests through the Availity provider portal, which serves as their primary multi-payer provider workspace. Klivira streamlines this by automating data submission directly to Availity. Additionally, Aetna supports X12 278 transactions via clearinghouses for applicable procedure categories, offering another electronic submission pathway for medical benefit PAs.

Pharmacy Benefit Prior Authorization for Tysabri

When Tysabri is covered under the pharmacy benefit (e.g., for outpatient retail or mail-order), PA requests are administered through CVS Caremark, Aetna's PBM. Submissions for retail pharmacy benefit PA route through established ePA partners such as CoverMyMeds and Surescripts. Klivira's platform integrates with these ePA partners to facilitate efficient electronic submissions for pharmacy-managed Tysabri.

Aetna's Medical Necessity Criteria and Policy for Tysabri

Aetna's medical necessity criteria for specialty drugs like Tysabri are published as Clinical Policy Bulletins (CPBs) in the public Aetna CPB library. These CPBs are versioned, dated, and provide the specific requirements for approval, including diagnosis, patient history, and often step-therapy protocols. Klivira's automation capabilities can help identify and apply the relevant CPB criteria during the submission process, ensuring documentation aligns with payer requirements.

Common Denial Reasons and Appeal Pathways for Tysabri

Denials for Tysabri prior authorizations often stem from insufficient documentation of medical necessity, lack of adherence to Aetna's step-therapy requirements as outlined in CPBs, or off-label use without compendium support. Aetna returns denial reasons via X12 835/277 transactions or portal status updates using CARC and RARC vocabularies. The appeal pathway typically involves reconsideration, peer-to-peer review, and formal appeals, with expedited options for urgent cases.

Turnaround Times and Electronic PA Posture

Aetna's PA turnaround times are governed by state-specific regulations and NCQA Utilization Management accreditation standards. For Medicare Advantage and Medicaid plans, CMS-0057-F mandates 72-hour standard and 24-hour expedited decisions, with phased compliance timelines. While Aetna participates in HL7 connectathons, specific Da Vinci PAS IG production conformance for medical benefit ePA requires direct verification of their current compliance disclosures.

Frequently asked questions

Which Aetna submission channels support Tysabri prior authorizations?

Aetna supports Tysabri prior authorizations through multiple channels depending on the benefit. Medical benefit PAs primarily route through the Availity provider portal and X12 278 transactions. Pharmacy benefit PAs, administered by CVS Caremark, utilize ePA partners like CoverMyMeds and Surescripts.

How do Aetna's medical and pharmacy benefits differ for Tysabri?

The distinction for Tysabri depends on its administration and Aetna's benefit design. Medical benefit typically covers infused Tysabri administered in a clinic or hospital, submitted via Availity or X12 278. Pharmacy benefit covers self-administered or retail/mail-order Tysabri, with PA requests processed through CVS Caremark and ePA partners.

Where can I find Aetna's medical necessity criteria for Tysabri?

Aetna publishes its medical necessity criteria for specialty drugs, including Tysabri, as Clinical Policy Bulletins (CPBs) in their public Aetna CPB library. These CPBs are the definitive source for specific requirements, review dates, and any applicable step-therapy protocols.

What are common reasons for Tysabri PA denials by Aetna?

Common denial reasons for Tysabri prior authorizations by Aetna include insufficient documentation of medical necessity, failure to meet step-therapy requirements as outlined in the relevant CPB, or requests for off-label use without supporting compendium evidence. Denials are communicated via X12 835/277 transactions or portal updates.

Does Aetna support electronic prior authorization (ePA) for Tysabri?

Yes, Aetna supports ePA for Tysabri, though the specific pathway varies. For pharmacy benefit Tysabri, ePA is supported through partners like CoverMyMeds and Surescripts. For medical benefit Tysabri, Aetna accepts X12 278 transactions, and its Availity portal facilitates electronic submissions. Klivira integrates with these systems to streamline the ePA process.

Related coverage

Other tysabri prior authorization by payer

Other tysabri prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo